Tag: GlobeNewswire

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.

Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) —  Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office (USPTO), further expanding the Company’s intellectual property portfolio relating to its proprietary mucoadhesive technology.

The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S. Patent Application No. 19/823,285.

The new application is part of Polyrizon’s broader patent family covering its proprietary mucoadhesive polymer technology. The technology is based on polymeric compositions designed for application to mucosal surfaces and capable of forming a continuous and durable layer upon contact with mucosal tissue.

The underlying technology is designed to support a range of potential applications, including the use of mucoadhesive formulations as a platform for the local or systemic delivery of therapeutic agents through mucosal tissues, including the nasal mucosa. The patent family describes the potential incorporation of therapeutic active ingredients into the mucoadhesive compositions, providing a technological foundation for the development of intranasal drug delivery systems.

The divisional filing enables Polyrizon to pursue additional patent protection for distinct aspects and applications of its technology while maintaining its connection to the Company’s existing U.S. patent family.

Tomer Izraeli, Chief Executive Officer of Polyrizon, commented: “This new U.S. patent filing represents another step in strengthening the intellectual property foundation supporting our intranasal technology platform. We believe our mucoadhesive technology has potential beyond stand-alone barrier applications, particularly as a platform for delivering therapeutic agents through the nasal mucosa. Pursuing additional  patent protection for these applications is an important part of our strategy as we continue to explore the broader potential of our technology.”

Polyrizon continues to develop its proprietary mucoadhesive technology for both stand-alone intranasal products and potential drug delivery applications. The Company believes the ability of its platform to provide prolonged interaction with mucosal surfaces may offer opportunities for the development of new approaches to local and systemic intranasal delivery.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential applications of its mucoadhesive technology, including as a platform for the local or systemic delivery of therapeutic agents through mucosal tissues; the potential benefits and opportunities associated with prolonged interaction with mucosal surfaces; the Company’s ability to obtain additional patent protection for its technology; and the Company’s plans to continue developing and exploring applications of its technology. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

GREENWICH, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) — Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced the opening of a new operational office in Houston, Texas. The Houston office will serve as a project execution hub supporting operations planning as the Company advances its lithium refinery in Muskogee, Oklahoma, complementing the Company’s existing Oklahoma City office and broader corporate footprint.

Houston, a world energy capital, was strategically selected for its deep concentration of engineering expertise, access to leading EPC and procurement talent, and established energy infrastructure ecosystem. The location strengthens Stardust Power’s ability to efficiently manage project development while embedding the Company within one of the world’s premier industrial and energy corridors.

Stardust Power expects to expand its Houston-based team as project execution accelerates, and the Muskogee refinery advances toward milestones. The office’s proximity to Oklahoma further supports efficient coordination and on-the-ground execution.

“The Houston office strengthens our operational footprint at a critical phase of development,” said Chris Celano, Chief Operating Officer of Stardust Power. “By building out a dedicated project management hub in one of the most experienced energy markets in the world, we are positioning the Company for execution as we advance the Muskogee refinery. This expansion reflects our commitment to deliver domestic, battery-grade lithium that supports U.S. energy security and industrial growth.”

The expansion reinforces Stardust Power’s commitment to building a resilient domestic battery material supply chain. As the United States accelerates energy transition initiatives and industrial reshoring efforts, the Company’s growing operational presence supports its long-term strategy to establish scalable U.S.-based lithium refining capacity and strengthen North American supply chain independence.

About Stardust Power

Stardust Power (NASDAQ: SDST) is building one of America’s largest battery-grade lithium carbonate refineries in Muskogee, Oklahoma, strategically located in the center of the United States’ growing energy and manufacturing corridor. The refinery is expected to have production capacity of up to 50,000 metric tons per annum and addresses the critical shortage of U.S. lithium refining capacity. Stardust Power is focused on building a resilient American battery supply chain.

For more information, visit www.stardust-power.com 

Stardust Power Contacts  

For Investors: 
Johanna Gonzalez 
investor.relations@stardust-power.com 

For Media:  
Michael Thompson  
media@stardust-power.com 

Cautionary Note Regarding Forward-Looking Statements 

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects. These statements may include, without limitation, statements regarding management’s expectations about future business strategies, financial performance, operating results, growth opportunities, market developments, competitive position, regulatory outlook, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “model,” “outlook,” “plan,” “predict,” “project,” “seek,” “target,” “will,” “could,” “should,” or similar expressions.

Forward-looking statements are not guarantees of future performance. They are based on current expectations, estimates, forecasts, and assumptions that involve significant risks and uncertainties, many of which are beyond the Company’s control and are difficult to predict. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including but not limited to: macroeconomic conditions; inflationary pressures; changes in interest rates; supply chain disruptions; evolving consumer demand; competitive and technological developments; regulatory or legal changes; litigation exposure; cybersecurity threats; and fluctuations in foreign exchange rates. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Except as required by law, the Company assumes no obligation and expressly disclaims any duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, even if subsequent events cause expectations to change.

You should consult our filings with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” section of its most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q, for additional detail about the factors that could affect our financial and other results.

ST. CLOUD, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary New Flyer of America Inc. (New Flyer), today announced that Washington Metropolitan Area Transit Authority (“Metro”) has exercised its second-year options under a five-year contract for 500 buses. The order includes 75 Xcelsior^® hybrid-electric forty-foot transit buses and 25 Xcelsior CHARGE NG™ battery-electric forty-foot transit buses. The options are being exercised from New Flyer’s Q2 2026 backlog.

Funding for these buses is sourced from a mix of federal, state, and local programs, including grants from the Federal Transit Administration’s Low or No Emission grant program. The new buses will replace retiring fleet units and are set to elevate passenger comfort and operational efficiency, aligning directly with Metro’s five-year Strategic Transformation Plan to become the region’s premier choice for safe and efficient transportation.

“Metro’s investment in our hybrid and battery-electric buses shows a strong commitment to efficiency and modernization,” said Chris Stoddart, President of North American Bus and Coach at NFI. “We’re proud to supply Buy America-compliant vehicles that support the agency’s innovation goals and boost local manufacturing across the country.”

”Our newest buses have enhanced safety features, give customers more room, improved comfort, and the latest onboard features to enhance their travel experience,” said Leroy Jones, Chief Operations Officer, Metro. “These vehicles represent an important investment in a modern fleet that better serves our customers today while preparing us for the future.”

Metro is recognized as the fifth-largest bus system nationwide, serving four million residents across 1,500 square miles spanning Washington, D.C., Maryland, and Virginia. The Metrobus system operates with a fleet of 1,300 vehicles, servicing 7,500 stops across the region. This year, Metro is celebrating 50 years of service.

This purchase of low- and zero-emission buses continues Metro’s progress under its five-year contract with New Flyer. In February 2025, New Flyer announced a base order for 100 hybrid-electric buses, followed by the announcement of Metro’s Year 1 options in February 2026 for an additional 75 Xcelsior^® forty-foot hybrid-electric buses and 25 Xcelsior CHARGE NG™ forty-foot battery-electric buses, strengthening Metro’s battery-electric fleet already serving the region.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer^® (heavy-duty transit buses), MCI^® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC^® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About New Flyer

New Flyer is North America’s heavy-duty transit bus leader and offers the most advanced product line under the Xcelsior^® and Xcelsior CHARGE^® brands. It also offers infrastructure development through NFI Infrastructure Solutions™, a service dedicated to providing safe, sustainable, and reliable charging and mobility solutions. New Flyer actively supports over 35,000 heavy-duty transit buses (New Flyer, NABI, and Orion) currently in service, of which 8,600 are powered by electric motors and battery propulsion and 1,900 are zero-emission. Further information is available at www.newflyer.com.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

For media inquiries, please contact:
Melissa Schnee
P: 385.910.6861
Melissa_Schnee@newflyer.com

For investor inquiries, please contact:
Stephen King
P: 204.792.1300
Stephen.King@nfigroup.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7741ba09-9f68-446c-b357-448824b31850

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Goldera Exploration Ltd. (“Goldera” or the “Company”) (TSX Venture Exchange: GERA) is pleased to provide an update on its on-going exploration activities at the high-grade Egan Gold Project in the world-class Timmins gold camp, Abitibi Greenstone Belt. In preparation for the upcoming drill program, these surface programs have been successful at exposing two additional subparallel structures to the high-grade gold E1 area structure, which was the initial discovery made on the Egan Gold Project. As a result, Goldera has potentially expanded the E1 discovery footprint from a single known structure to a broader, multi-structure gold system.

Key Highlights:

• The ongoing trenching and mapping program identified two new subparallel structures at the E1 footwall displaying similar alteration, quartz veining and structural characteristics known to carry gold mineralization at the E1 initial discovery zone, expanding the potential mineralized zone to ~250 metres across strike and 450 metres along strike, broadly parallel to the syenite-country rock contact.
• The August program included 15 trenches, 488 soil samples, 136 rock grab samples and 222 saw-channel samples. Assay results remain pending.
• Additional stripping planned at E1, with E2 and E3 scheduled for later follow-up work.
• Drill planning is underway, expected to refine and finalize targets by Q4-2026 based on results of the current surface exploration program.
• Egan is a 111 km² district-scale property ~50 km from Timmins, with four previously identified gold occurrences and historical surface samples up to 105 g/t Au at E1. 

“The discovery of two additional structures with geological characteristics similar to the high-grade E1 occurrence materially expands the exploration potential of this part of Egan,” said Charles Tarnocai, CEO & Director of Goldera. “Importantly, we are no longer looking at E1 as an isolated surface occurrence, we are seeing evidence of a broader structural framework extending across hundreds of metres, with the newly exposed structures potentially sharing similar alteration, quartz veining and orientation to the original E1 discovery.”

Surface Stripping Expands the E1 Gold System

Goldera’s ongoing surface stripping and channel sampling program, which initially focused on the E1 area, has identified two additional subparallel structures within the footwall of the high-grade E1 gold occurrence, expanding the area of interest around the Company’s initial discovery. The newly exposed structures, identified in trenches TR2 and TR5, display similar alteration and quartz-veining characteristics to E1, including intense iron-carbonate-specularite-silica alteration and pyrite within the northeasterly trending shear zones. The structures occur over an area extending approximately 250 meters into the E1 structure footwall and 450 meters along strike, and are broadly parallel to the syenite contact within the surrounding country rock mafic volcanic units and gabbro, to the north (refer to Figure 2). The true width of the altered structures exposed are up to 50cm. As with E1, the wall rocks to these structures host northerly trending quartz veinlet zones. At E1, visible gold is observed in quartz veins with similar orientation and crack-seal textures (refer to Figure 3). This suggests that gold is not only associated with the northeasterly trending structures, but quartz vein arrays in their wall rocks, potentially presenting a bulk tonnage opportunity. The August exploration program consisted of prospecting, soil geochemical sampling, mapping and the excavation of 15 trenches. In total, 488 soil samples, 136 rock grab samples and 222 saw channel samples (including QA/QC) were collected and sent for analysis. Sample results are pending from the surface stripping and soil sampling conducted on the property. Following the field crew break concluding at the end of this month, additional surface stripping is planned to further expose structures in the E1 area where permits allow. Permits are available for stripping at E3 target, and work at E2 is pending a crossing permit for a narrow creek. Permits for additional trenching and stripping in the E1 area will also be prepared.

Figure 1: Regional location of Egan Gold Project.

Figure 2: Trenched and stripped areas in the E1 gold occurrence area. Altered structures similar to that identified at the high-grade gold E1 showing are identified in trenches TR2 and TR5. These structures have a similar trend and dip direction, identified in an area of 250m across strike and ~450m along strike. Inferred strike extensions of those structures are shown as dashed red lines, with uncertain extents. Fault kinematics are from field observations. The inset shows the extent of all trenching in the current, on-going program, with the external property boundary denoted as a heavy black line. For regional location reference, refer to Figure 1.

Figure 3: Visible gold with pyrite in quartz veining in hanging wall of the E1 gold occurrence. Similarly oriented quartz-veins with crack-seal textures are observed in newly exposed structures. Location 48.4114561°N, -80.6791542°W.

Egan Gold Project Overview

The Egan Gold Project comprises 449 claims covering ~111 km², located approximately 50 kilometers from Timmins within the prolific Abitibi Greenstone Belt of Ontario, a region with a long history of prominent gold discoveries and active operations. The district-scale project hosts an overlooked syenite-hosted gold system with both high-grade and bulk-tonnage exploration potential. Despite being located close to one of the largest gold producing camps in the world, Egan is a new discovery with very limited past work. Previous work defined four gold occurrences at areas E1, E1S, E2 and E3, returning numerous high-grade gold results in grab samples, up to 105.0 g/t Au at E1 area and grab samples recorded up to 44.7 g/t Au and 19.0 g/t Au at E3 area, demonstrating the presence of robust gold-bearing structures at surface across a broad area. From a regional exploration perspective, Egan is positioned within a structurally favorable portion of the Abitibi Greenstone Belt, about 8 kilometers south of the Destor–Porcupine deformation zone (refer to Figure 1).

The Egan Gold property is under option agreement with Harfang Exploration Inc., allowing Goldera to earn up to 80% interest (refer to Fancamp Exploration Ltd. press release dated November 12, 2025). Goldera is currently in the first, 40% earn-in phase of the option agreement, an initial phase that should be completed with the program outlined above.

Qualified Person
The technical information contained in this press release was reviewed and approved by François Auclair, PGeo, M.Sc. Vice President Exploration of Goldera, designated as a Qualified Person under National Instrument 43-101. M Auclair, the Company’s qualified person and an officer, has reviewed and approved the technical disclosure contained in this news release.

Quality Assurance and Quality Control
François Auclair, PGeo, M.Sc., a Qualified Person as defined by National Instrument 43-101, is responsible for the on-going drilling and sampling program, including quality assurance (QA) and quality control (QC). Assays for the soil sampling and trenching were respectively analyzed by ALS Canada Ltd. and Techni-Lab, a subdivision of Actlabs. The Corporation inserts quality control samples (blanks, standard reference material, and duplicates) at regular intervals to monitor laboratory performance.

About Goldera Exploration Ltd.

Goldera Exploration Ltd. (TSX-V:GERA) is a discovery-driven Canadian gold and copper exploration company advancing a portfolio of high-potential exploration assets across Canada’s premier mining districts. Goldera is focused on unlocking value through systematic exploration of district-scale gold and copper projects in Ontario, Québec and New Brunswick, with interests in the Yukon, supported by an experienced technical and capital markets team. Goldera is advancing exploration at its flagship Egan Gold mineral project in Ontario’s Abitibi Greenstone Belt and the Acadian Gold Corp. joint venture in New Brunswick’s emerging gold-copper district.

Further information on Goldera can be found at: www.golderaexploration.com

Website | LinkedIn | X/Twitter

For Further Information

Charles Tarnocai, CEO & Director, Goldera Exploration Ltd.
info@golderaexploration.com

Tara Asfour, Communications & Marketing
tasfour@golderaexploration.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements“) within the meaning of Canadian and United States securities legislation. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements in this news release relate to, among other things: the Company’s strategic plans; the composition and timing of completion of the Company’s exploration and drill programs on the Egan Gold Project and the McIntyre Brook and Riley Brook mineral properties held by Acadian Gold; the anticipated objectives, benefits and results of the Company’s exploration programs, including the aim of such programs to test multiple high-priority targets and expand areas of known gold mineralization, with the intention of follow-up drilling in late Q3 – early Q4 of this year; the intended use of proceeds from Goldera’s previously completed financing; estimates of mineralization from drilling; geological information projected from sampling results; and the potential quantities and grades of the target zones.

These forward-looking statements reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include, among other things: conditions in general economic and financial markets; the benefits to be derived from the Company’s proposed exploration programs; accuracy of assay results; geological interpretations from drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; the historical basis for current estimates of potential quantities and grades of target zones; the availability of skilled labour and no labour related disruptions at any of the Company’s operations; no unplanned delays or interruptions in scheduled activities; all necessary permits, licenses and regulatory approvals for operations are received in a timely manner; the ability to secure and maintain title and ownership to properties and the surface rights necessary for operations; and the Company’s ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.

The Company cautions the reader that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements contained in this news release and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; changes in commodity prices; changes in interest rates; failure to delineate potential quantities and grades of the target zones based on historical data; risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government or regulatory approvals, industrial disturbances or other job actions, and unanticipated events related to health, safety and environmental matters); risks relating to adverse weather conditions; political risk and social unrest; general market and industry conditions; and those factors identified under the caption “Risks Factors” in the Company’s Form 2B Listing Application dated July 29, 2026.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Figures accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/d904ae99-92b8-4f50-be37-4be8c5602d35
https://www.globenewswire.com/NewsRoom/AttachmentNg/6334ffc8-7847-4be5-a376-a46d9a96ac3a
https://www.globenewswire.com/NewsRoom/AttachmentNg/10e4ae4d-afe7-4e9e-be78-6e8d71c05d07

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026

Initial clinical data expected in the second half of 2027

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) —  Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CR-002, a topoisomerase inhibitor antibody drug-conjugate (ADC) targeting programmed cell death ligand 1 (PD-L1), being developed for the treatment of advanced solid tumors.

“FDA clearance of the CR-002 IND is an important milestone for Crescent and is the third distinct program in our portfolio to enter the clinic,” said Ellie Im, M.D., chief medical officer of Crescent. “The strong scientific rationale and encouraging preclinical profile of CR-002 underscores its promise in addressing a range of solid tumors. We look forward to initiating the APOLLO trial this quarter and working with global investigators to generate important clinical insights and advance our mission of bringing new treatment options to patients living with difficult-to-treat cancers.”

The Phase 1/2 APOLLO global clinical trial plans to enroll patients in the United States, Europe and Asia Pacific with advanced solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. The study’s dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants with the opportunity for additional participants in expansion cohorts. Crescent anticipates reporting initial clinical data from the APOLLO trial in the second half of 2027, including safety, pharmacokinetic and preliminary antitumor activity in multiple tumor types.

About CR-002
CR-002, internally developed in collaboration with Paragon Therapeutics, is a topoisomerase inhibitor ADC directed to PD-L1, a validated target known to have high expression in multiple solid tumors and comparatively limited expression in healthy tissue. CR-002 incorporates a PD-L1 antibody selected for high internalization to facilitate payload release in target cells and a linker designed for intracellular cleavage and high stability in circulation, an approach intended to concentrate payload delivery in tumor tissue. APOLLO, a global Phase 1/2 trial of CR-002 in patients with solid tumors, is anticipated to commence in the fourth quarter of 2026. Crescent also plans to evaluate CR-002 in combination with CR-001, its PD-1 x VEGF bispecific antibody, as part of its efforts to evaluate synergistic ADC and immuno-oncology combinations.

About Crescent Biopharma 
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Forward-Looking Statements 
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, beliefs, or strategies regarding the future of its pipeline and business including, without limitation: the initiation, design, timing, and success of the Phase 1/2 global APOLLO trial; the potential for CR-002 to treat a range of solid tumors; and anticipated timing of reporting proof-of concept data from the APOLLO trial. Forward-looking statements generally relate to future events or future financial or operating performance. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects and involve a number of risks, uncertainties or other assumptions that may cause actual performance to be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties include, but are not limited to: the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized or may take longer to realize than anticipated; Crescent’s limited operating history, including with respect to clinical trials; Crescent’s historical losses and any future ability to generate revenue; Crescent’s ability to raise capital to support its business plans; risks associated with clinical development and regulatory approval; risks related to Crescent’s intellectual property; Crescent’s reliance on third parties, including to help develop its product candidates, run its clinical trials, and manufacture its product candidates; significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks; risks related to the current macroeconomic environment, including fluctuating interest rates, barriers to trade, changes to fiscal and monetary policy or government budget dynamics, geopolitical factors, including the ongoing conflicts in Iran and between Russia and Ukraine and the responses thereto, and supply chain disruptions, as well as those factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent’s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

– In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I, a blood marker of heart muscle injury, declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)

– 54% of BBP-418-treated individuals had stable or improved LVEF at Month 12 versus 25% in the placebo arm (p=0.0262)

– In data presented separately, BBP-418 treatment of LGMD2I/R9 in FORTIFY increased mean glycosylated αDG by Month 3 to the levels of asymptomatic heterozygous FKRP carriers, who do not exhibit disease; this result was sustained through Month 12

– Taken together, these findings support the potential of BBP-418 to act as a disease modifying therapy by addressing the condition at its source

– BBP-418 is under FDA Priority Review with a PDUFA target action date of November 27, 2026

PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today presented new exploratory cardiac data from the 12-month interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418 in individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). The data were presented in an oral presentation at the 31st annual Congress of the World Muscle Society in Hiroshima, Japan by Volker Straub, M.D., Ph.D. of Newcastle University, UK.

“Cardiac involvement is a major driver of morbidity and mortality in LGMD2I/R9, which is why it remains one of the greatest concerns for people living with the condition, families and treating physicians. Historically, we have been able to monitor the heart and manage complications, but we have not been able to address the underlying cause of the disease,” said Dr. Straub. “What stands out in this analysis is how consistent it is: high-sensitivity troponin I fell and, in those who entered the study with elevated levels, it normalized; ejection fraction stabilized; and this happened alongside walking farther and breathing better. It’s encouraging to see that the therapeutic approach seems to work across the whole muscular system, including the heart.”

Cardiomyopathy affects approximately 30% of individuals with LGMD2I/R9 and approximately 60% of those with other FKRP genotypes, and is progressive, with an annual loss of approximately 0.4% of left ventricular ejection fraction (LVEF). In FORTIFY, 22.9% of participants (25/109) had elevated high-sensitivity (HS) troponin I at baseline and 17.1% (18/105) had an LVEF below 50%. Exploratory cardiac findings at Month 12 showed:

• HS troponin I is a blood test used to detect injury to heart muscle. 100% of the participants treated with BBP-418 returned to the normal range for HS troponin l by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)
• At Month 12, 54% of participants treated with BBP-418 had stable or improved LVEF, a measurement of how much blood the heart’s main chamber pushes out with each beat, compared with 25% of those on placebo (p=0.0262)
• Both HS troponin I and LVEF will continue to be monitored in the ongoing FORTIFY study

A consistent pattern across the FORTIFY interim analysis is the proportion of treated individuals reaching normal or near-normal levels on markers of the disease e.g., 38% of patients whose CK reached normal levels. In addition to the HS troponin I finding, in which 100% of evaluable BBP-418-treated participants with elevated levels at baseline returned to the normal range by Month 12, separate data presented at WMS 2026 by Anne Katrine Kjemsø Jensen, a medical student in the laboratory of John Vissing M.D., D.M.Sci., Copenhagen Neuromuscular Center of Rigshospitalet, DK, quantified αDG glycosylation in 34 asymptomatic heterozygous FKRP carriers. Results showed:

• Asymptomatic carriers showed significantly reduced glycosylation versus healthy controls, thereby establishing a reference point for the level associated with normal muscle function (34% of control)
• In FORTIFY, BBP-418 treatment increased mean glycosylated αDG above carrier levels by Month 12, suggesting that BBP-418 can restore glycosylated αDG to asymptomatic levels
• While many therapies in progressive neuromuscular disease aim to slow decline, BBP-418 was developed to target LGMD2I/R9 at its source, and the pattern of biomarker normalization observed to date, alongside functional improvement from baseline rather than stabilization, is consistent with the potential for BBP-418 to be a disease modifying therapy

In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis, showing treated individuals improving while placebo recipients declined across every key measure. These results were presented as a late-breaking oral presentation at the 2026 MDA Clinical and Scientific Conference, which are available here.

BridgeBio believes BBP-418 is positioned to become the first and only approved therapy for individuals living with LGMD2I/R9, addressing a significant unmet need in this disease and potentially representing the first approval of a therapy for any form of LGMD. Approximately 7,000 individuals currently live with LGMD2I/R9 and other addressable α-dystroglycanopathies in the U.S. and Europe. BBP-418 is under FDA Priority Review with a PDUFA target action date of November 27, 2026. The Company is also engaging regulatory agencies to identify an expedited path to approval for BBP-418 in Europe.

BBP-418 has previously received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the European Medicines Agency (EMA). BBP-418 received Priority Review from the FDA, highlighting the potential for BBP-418 to address unmet need in LGMD2I/R9. Consistent with Rare Pediatric Designation from the FDA, if BBP-418 is approved, BridgeBio may qualify for a Priority Review Voucher. The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age in the first half of 2027 and in LGMD2M/R13 and LGMD2U/R20 in the near future.

About Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
LGMD2I/R9 is a monogenic autosomal recessive disease caused by partial loss of function mutations in the fukutin-related protein (FKRP) gene, and FKRP mutations impair glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells. Clinical manifestations typically present as a skeletal myopathy affecting the lower and then upper limbs, which is commonly later accompanied by pulmonary muscle and cardiac muscle involvement. Individuals who harbor a homozygous L276I genotype typically develop disease manifestations during late childhood with progression to loss of independent ambulation (25%), assisted ventilation (10%), and cardiomyopathy (30%) in adulthood. Cardiomyopathy is progressive, with an annual loss of 0.4% of left ventricular ejection fraction (LVEF). Individuals with other FKRP genotypes typically have an earlier childhood onset with a more severe clinical course, rapid loss of mobility by 20 years of age, more frequent cardiac involvement (60%), and eventual pulmonary decline by 30 years of age in nearly all cases.

About BBP-418
BBP-418 is an investigational oral glycosylation substrate therapy with potential to be the first and only therapy for LGMD2I/R9. BBP-418 is designed to saturate the partially functional FKRP enzyme with substrate thereby enhancing residual FKRP function and restoring glycosylation of αDG. Through restoration of αDG glycosylation, BBP-418 may stabilize or improve muscle function, including gross motor, ambulatory, and cardiopulmonary function.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of data regarding BBP-418, including the potential for BBP-418 to act as a disease-modifying therapy for LGMD2I/R9, restore or normalize disease biomarkers, and stabilize or improve cardiac, gross motor, ambulatory and pulmonary function; the potential for BBP-418 to become the first and only approved therapy for individuals living with LGMD2I/R9 and potentially the first approved therapy for any form of LGMD; the timing and likelihood of potential regulatory approval and commercialization of BBP-418, including the PDUFA target action date of November 27, 2026; BridgeBio’s interactions with regulatory authorities regarding a potential expedited path to approval for BBP-418 in Europe; BridgeBio’s potential eligibility to receive a Priority Review Voucher if BBP-418 is approved; the continued evaluation of cardiac and other clinical measures in the ongoing FORTIFY study; and BridgeBio’s plans to initiate additional clinical studies of BBP-418, including in individuals with LGMD2I/R9 less than 12 years of age and in individuals with LGMD2M/R13 and LGMD2U/R20. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s preclinical studies and clinical trials not being indicative of final data; the exploratory and non-alpha-controlled nature of certain analyses described in this press release and the small sample sizes on which certain of those analyses are based; that observed biomarker changes, including normalization of HS troponin I, glycosylated αDG or other disease markers, may not be replicated in additional analyses or studies or predict or translate into long-term clinical benefit, sustained improvement in cardiac or other muscle function, or prevention of disease progression; that BBP-418 may not demonstrate the anticipated efficacy, safety, therapeutic benefit or disease-modifying potential in ongoing or future clinical studies; that the design, enrollment, conduct, timing and success of ongoing and planned clinical trials may differ from current expectations; that the FDA or other regulatory authorities may not approve BBP-418 on the anticipated timeline or at all, may not agree with BridgeBio’s regulatory approval strategies, clinical trial designs, conduct or methodologies, or the sufficiency of data submitted, or may require additional data, studies or other information; that BBP-418 may not become the first and only approved therapy for LGMD2I/R9 or the first approved therapy for any form of LGMD; that BridgeBio may not identify or obtain an expedited path to approval for BBP-418 in Europe; that BridgeBio may not qualify for or receive a Priority Review Voucher; that plans to initiate additional clinical studies, including studies in individuals less than 12 years of age or in other forms of LGMD, may be delayed, modified or may not occur as expected; the potential size of the target patient populations BBP-418 is designed to treat not being as large as anticipated; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com  
(650) 789-8220

BridgeBio Investor Contact
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Canadian Goldfields Discovery Corp. (TSX-V: CGM, OTCQB: CGMXF) (“Canadian Goldfields” or the “Company”) is pleased to announce the completion of soil geochemistry and upcoming commencement of a property-wide airborne magnetic survey at its 6,366-hectare Miminiska Gold Project in northwestern Ontario. The programs are intended to identify new exploration targets, support future drilling and further define regional controls on gold mineralization.

Construction of a winterized exploration camp is underway at Miminiska to support continued field activities and future drilling. Approximately 40% of current site staff are members of the Eabametoong First Nation (“EFN”).

Ian Dasti, Vice-President of Exploration, P.Geo., commented: “We have a 14-kilometre prospective trend at Miminiska with historical drilling concentrated at the Miminiska and Frond Zones, leaving more than 12 kilometres of strike largely untested. Our current programs are designed to systematically evaluate this broader opportunity. By integrating soil geochemistry with property-wide airborne magnetics and our existing geological data, we aim to improve our understanding of the controls on gold mineralization and advance growth-focused target generation for future drilling.”

Highlights

• Growth-Focused Target Generation: Soil geochemistry and upcoming property-wide airborne magnetics will be integrated with geological data to develop new exploration targets for future drilling.
• Systematic Geochemical Coverage: 329 soil samples collected between Frond and Wottam Lake on a 50 m × 100 m grid, with assays pending.
• Property-Wide Airborne Geophysics: HeliGT airborne magnetic survey expected to commence before the end of October to further define geological and structural controls on gold mineralization.
• Winter Exploration Infrastructure: Winterized exploration camp under construction to support continued field activities and future drilling.
• Strong Local Participation: 40% of current Miminiska site staff are members of Eabametoong First Nation.

Soil Geochemistry

The Company completed 329 soil samples, including quality-control samples, along 39 Ha of the prospective trend between Frond and Wottam Lake on a 50-metre by 100-metre grid. The program is designed to:

• Initiate systematic geochemical coverage across prospective ground between Frond and Wottam Lake;
• Identify gold and trace-element geochemical patterns for follow-up exploration; and
• Support target generation through integration with geological mapping, historical data and airborne geophysics.

Samples have been submitted to Activation Laboratories Ltd. (“Actlabs”) for gold and trace-element analysis, with results anticipated before the end of October 2026.

Airborne Geophysics

The Company is preparing to commence a HeliGT airborne magnetic survey across the entire Miminiska Property using SHA Geophysics. The survey is designed to:

• Provide high-resolution magnetic coverage across the 6,366-hectare Project;
• Further define geological and structural controls on gold mineralization; and
• Support target generation through integration with soil geochemistry, geological mapping and historical data.

The survey is expected to commence before the end of October 2026.

Winter Exploration Camp

Construction of the Company’s winterized exploration camp at Miminiska is underway to support continued field activities and future drilling.

Approximately 40% of current Miminiska site staff are members of Eabametoong First Nation (“EFN”). Canadian Goldfields continues to work collaboratively with EFN as exploration activities at Miminiska advance.

Selected Historical Drill Results

Approximately 28,000 metres of historical drilling has been completed at Miminiska, concentrated principally at the Miminiska and Frond Zones. Selected historical drill results are presented below. These results are historical in nature, have not been independently verified by the Qualified Person and are reported as core lengths that do not necessarily represent true widths.

Area	Hole ID	Azimuth (°)	Dip (°)	From (m)	To (m)	Interval (m)	Au (g/t)
Miminiska	0603-08	358.4	-70	51.94	72.78	20.84	5.75
Miminiska	88C-10	315	-50	65.38	69.34	3.96	12.69
Miminiska	0603-18	358.1	-50	120.57	131.75	11.18	4.49
	including			120.57	124.30	3.73	7.29
Miminiska	0604-32	358	-66	235.78	241.10	5.32	13.95
Frond	87-13	144	-50	125.79	127.10	1.31	14.74
Frond	87-10	144	-45	67.79	69.04	1.25	7.53
Frond	87-14	144	-65	61.66	62.00	0.34	37.02
Frond	87-15	144	-70	92.20	93.15	0.95	11.32

NI 43-101 Technical Report on the Miminiska Property, Northern Ontario, Canada, prepared by APEX Geoscience Ltd. for Canadian Goldfields, authored by Qualified Persons Edward Parker, B.Sc., P.Geo., and Eliza D. Verigeanu, M.Sc., P.Geo. Frond Zone results adapted from Neal & Miller Report, 1987. Effective date of December 1, 2025.

About Canadian Goldfields Discovery Corp.

Canadian Goldfields Discovery Corp. is a Canadian mineral exploration company focused on advancing district-scale gold opportunities in Ontario, Canada. The Company’s portfolio includes the flagship Miminiska Gold Project in northwestern Ontario and the Swayze Central Gold Property located within the prospective Swayze Greenstone Belt near Timmins.

Miminiska hosts a gold-rich banded iron formation (“BIF”) system with multiple high-grade intercepts drilled across the Miminiska and Frond Zones and more than 14 km of underexplored strike extent. Supported by approximately 28,000 m of historical drilling, the project demonstrates significant scale potential with mineralization remaining open along strike and at depth. The Swayze Central Gold Property complements the Company’s portfolio with historical high-grade gold occurrences and additional district-scale exploration upside in one of Canada’s most established mining regions.

Canadian Goldfields is led by a lean and execution-focused leadership team committed to disciplined exploration, systematic discovery and long-term value creation through the advancement of high-quality gold assets in tier-one mining jurisdictions.

On behalf of the Company,
John G. Booth, Chief Executive Officer and Director

Additional Information
Harp Gosal | Director of Capital Markets & Communications
Canadian Goldfields Discovery Corp.
Phone: (604) 218-1142
Email: hgosal@canadiangoldfields.com

Qualified Persons and Technical Disclosure

The scientific and technical information contained in this news release has been reviewed and approved by Ian Raymond Dasti, P.Geo, Vice-President of Exploration of Canadian Goldfields Discovery Corp., and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI-43101”).

Mr. Dasti has reviewed the technical information disclosed in this news release and has approved its dissemination. The information presented herein relates to planned exploration activities at the Company’s Miminiska Gold Project, including the design and objectives of the geochemical soil sampling program.

Historical exploration information referenced in this news release has been compiled from publicly available sources and historical reports. A Qualified Person has not completed sufficient work to independently verify all historical information, and the Company is not treating such information as current mineral resources or mineral reserves as defined by NI 43-101. Historical results, mineral occurrences, and exploration data should not be relied upon as indicative of future exploration results.

The Company considers historical exploration information to be relevant for the purpose of guiding future exploration programs; however, readers are cautioned that such information may not be representative of actual mineralization or exploration potential on the Property.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the Company’s planned exploration program for the Miminiska Gold Property is subject to change. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company does not undertake to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

NEW YORK and SEOUL, South Korea, Oct. 05, 2026 (GLOBE NEWSWIRE) — Nexus Advanced Technologies Inc. (Nasdaq: NXAT), formerly K Wave Media Ltd. (the “Company”), today announced that it has entered into an ATM Consent, Note Repayment and Warrant Exchange Agreement (the Note and Warrant Restructuring Agreement”), effective as of October 2, 2026, with Anson Investments Master Fund L.P. and Anson East Master Fund L.P. (collectively, the “Anson Funds”).

The Note and Warrant Restructuring Agreement is intended to simplify the Company’s capital structure and support future financing as management evaluates potential acquisitions, mergers and other strategic transactions across the AI ecosystem and advanced technologies. There can be no assurance that any transaction will be pursued or completed.

Under the Note and Warrant Restructuring Agreement, i) full payment of $2.5 million will make the remaining note convertible solely at a fixed price equal to the average daily VWAP for the three trading days immediately preceding full payment, with its anti-dilution, price-reset and similar adjustment provisions ceasing to apply. ii) Anson may, at its discretion, exchange warrants covering 8,310,250 ordinary shares for an aggregate of 4.5 million ordinary shares, subject to ownership limits and specified adjustments; delivery of the corresponding exchange shares cancels the exchanged warrants, and completion of the full exchange eliminates their anti-dilution and price-adjustment provisions. The cashless exchange provides no cash proceeds to the Company and will dilute existing shareholders. iii) Anson has also consented to an ATM offering during the agreed consent period at a minimum public offering price of $2.00 per ordinary share. Existing adjustment provisions continue until the applicable payment or exchange milestone is completed, and other note terms and specified financing restrictions, participation rights, repayment rights and security arrangements remain in effect except as expressly amended or waived.

“Our objective is to make our capital structure more predictable as we pursue future financing and evaluate strategic acquisitions and other transactions,” said Myungjong Kim, Co-Chief Executive. “Completing the agreed payment and other requirements per the agreement will eliminate variable conversion pricing and anti-dilution adjustments from the remaining note, while completing the warrant exchange will retire the exchanged warrants and their adjustment provisions.”

The Company will furnish the Note and Warrant Restructuring Agreement and this release to the Securities and Exchange Commission on Form 6-K. Investors should review the Note and Warrant Restructuring Agreement for the complete terms, conditions and continuing obligations.

About Nexus Advanced Technologies
Nexus Advanced Technologies Inc. (Nasdaq: NXAT) pursues strategic investments, acquisitions and partnerships across AI infrastructure and advanced technologies, including data centers, AI compute and GPU infrastructure.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the ATM offering, the application of ATM proceeds, the repayment and conversion of the Note, the exchange of warrants for ordinary shares, the Company’s capital structure and financial flexibility, and the Company’s evaluation of potential strategic transactions.

These forward-looking statements are based on management’s current expectations, assumptions and estimates and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including: general market and economic conditions; the Company’s ability to conduct the ATM offering on anticipated terms or at all; the Company’s ability to make the required payments under the Agreement; the timing and amount of any warrant exchanges; the Company’s ability to identify, negotiate and consummate any strategic transaction; and the risks and uncertainties described in the Company’s most recent Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission.

The Company can provide no assurance that it will enter into or consummate any strategic transaction, or that any such transaction, if completed, will achieve its intended benefits.

All forward-looking statements speak only as of the date of this press release and are qualified in their entirety by reference to the factors discussed in the Company’s filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Investor Relations: info@kwavemedia.com
Public Relations: info@redroosterpr.com

Transaction supports ownership of key cultivation and production infrastructure in Two Core Markets

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that VIREO PROPERTY HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), VIREO PROPERTY HOLDINGS NEW YORK, LLC, a Delaware limited liability company (“Holdings NY”), VIREO PROPERTY HOLDINGS FLORIDA, LLC, a Delaware limited liability company (“Holdings FL”), 256 COUNTY ROUTE 117 PERTH LLC, a Delaware limited liability company (“NY PropCo”), and 160 COMFORT ROAD, LLC, a Delaware limited liability company (“FL PropCo”, and together with Holdings, Holdings NY, Holdings FL and NY PropCo, collectively, the “Borrower”), have entered into a US$60 million real estate financing (the “Loan”) with a U.S. commercial bank and institutional lender, related to the cannabis cultivation and production facilities located in Johnstown, New York and Palatka, Florida (collectively, the “Properties”). Approximately US$49 million of the financing proceeds are being used to refinance existing senior debt that was entered into in connection with the previously announced option to purchase the Johnstown facility and approximately US$11 million of the financing proceeds are being used to finance the acquisition of the Palatka facility. The Palatka facility is a significant cultivation and production asset supporting the Company’s Green Dragon operations and is an important component of Vireo’s strategy to build scale and strengthen its vertically integrated platform in Florida. The Palatka facility was previously leased from Rainbow Palatka FL LLC (“Rainbow”). In connection with the acquisition of the Palatka facility, the existing lease with Rainbow will be terminated and a new lease with Green Dragon Florida LLC, an affiliate of Vireo, will be executed. The US$60 million loan bears interest at 8.5% per annum and matures on April 2, 2034. The Loan is secured by a first-priority mortgage on the Properties, a first priority pledge of membership interests by each of Vireo Health Inc., a wholly owned subsidiary of Vireo, Holdings, Holdings NY and Holdings FL in their respective wholly owned subsidiaries comprising Borrower, a security interest in substantially all personal property of the Borrowers and other loan parties and is subject to customary terms and conditions.

“This $60 million credit facility is an important milestone for Vireo and directly supports our strategic growth plans,” said Tyson Macdonald, Chief Financial Officer of Vireo Growth. “The facility carries an 8.5% interest rate, among the most attractive rates in the cannabis sector, and reflects the strength of our business and continued access to institutional capital as we execute on our growth strategy. We look forward to working with the lender as a long-term banking partner for our future capital needs.”

Additional information regarding the financing and its material terms and conditions will be included in the Company’s regulatory filings.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Information

This press release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred to herein as “forward-looking information”). Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the expected benefits of the ownership of the Properties; and the Company’s expectations regarding its ability to service the Loan. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release and are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the Company’s ability to service the Loan; risks that the anticipated benefits of the ownership of the Properties may not be realized; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties in connection with the Properties; the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission at www.sec.gov and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

For Vireo, contact:

Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com
781-956-7052

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) is pleased to announce it has completed a first gold pour at its Galam pilot plant in Senegal.

Highlights

• First gold doré pour achieved on September 30, 2026 with gold-silver cement from the Merrill-Crowe circuit.
• Plant run time and gold recovery are increasing steadily since completion of commissioning.
• Next step is to ramp up production to nameplate capacity.

Daniel Misiano, President & CEO of Dynacor, commented: “We are delighted to highlight our first gold pour on the continent of Africa, marking our transition into a geographically diversified gold processor. Galam is now the first gold processing plant servicing permitted ASGM in Senegal and poised to deliver strong benefits to stakeholders as we showcase our platform in Africa.

We would like to extend our sincere thanks to the experienced team who drove the construction and commissioning of the Galam modular plant. Their tremendous efforts and commitment to excellence accelerated construction of the plant over a 10-month period and with no lost-time injuries.”

Figure 1: Introducing the Team Behind Dynacor’s First Senegalese Gold Pour

Figure 2: Introducing Dynacor’s First African Bar

About the Galam Plant

Dynacor’s wholly owned Galam subsidiary hosts a 50-tpd modular processing plant that will serve as a test ground for Dynacor’s expansion into Senegal and Africa at large. Galam’s location in Kédougou places it at the heart of the main Artisanal and Small-Scale Gold Mining (ASGM) region in Senegal where some 98% of national ASGM sites and 13/16 government-permitted ASGM corridors are located. If successful, the Galam pilot plant will be a precursor to a 300-tpd commercial processing plant in Senegal.

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236

E: investors@dynacor.com
Website: https://dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com  
Website: www.renmarkfinancial.com

Photos accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/f0b94e1d-8a6a-47ea-8e0a-81eca3b896c2

https://www.globenewswire.com/NewsRoom/AttachmentNg/96a571b0-6185-4986-8bf7-d5abb286ea91